Irritable Bowel Syndrome Treatment Market to Surpass US$ 2,300 Million Threshold by 2025
The Global Irritable Bowel Syndrome Treatment Market by drug type (lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others), medical condition (IBS-constipation and IBS-diarrhea), distribution channel (hospital pharmacies, online pharmacies, and retail pharmacies) and region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 726.1 million in 2016 and is projected to exhibit a CAGR of 12.9% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Growing prevalence of irritable bowel syndrome associated with lifestyle factors, stress, and increasing number of options for the treatment are expected to be the major factors driving the growth of the global irritable bowel syndrome treatment market over the forecast period.
Inquire for Sample Copy at: https://www.coherentmarketinsights.com/insight/request-sample/506
Manufacturers are focusing on upgrading the available treatment options as well as developing new solutions for symptom specific irritable bowel syndrome. Allergan plc received the U.S. Food & Drug Administration (FDA) approval for Viberzi (eluxadoline) for the treatment of IBS in adult men and women in 2015. Also, the company received approval of Health Canada for IBS-D in 2017. Valeant Pharmaceuticals International, Inc. received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan for the treatment of IBS-D in 2015.
The major players are also expanding the product portfolio and their IBS therapies through mergers and acquisitions. Valeant Pharmaceuticals International, Inc. acquired Salix Pharmaceuticals, Inc. in 2015 along with the latter’s popular brand Xifaxan. The manufacturers are spreading the awareness about IBS through direct-to-consumer campaign advertisements for IBS drugs. For instance, Allergan and Ironwood Pharmaceuticals launched the first DTC campaign for Viberzi in 2015.
Manufacturers are focusing on developing novel gastrointestinal therapies for the treatment of irritable bowel syndrome by actively investing in research and development of pipeline products. For instance, Synergy Pharmaceuticals, Inc. announced the acceptance of supplemental new drug application for Trulance (Plecanatide) for IBS treatment in 2017. Furthermore, Sucampo Pharmaceuticals, Inc.’s pipeline products include lubiprostone for pediatric functional constipation (6 years – 17 years) in phase two and lubiprostone alternate formulation for pediatric constipation (6 months – 6 years). Also, Ardelyx, Inc. reported successful phase 3 T3MPO trial of Tenapanor in patients with irritable bowel syndrome with constipation. Astellas Pharma, Inc. is conducting clinical trials for ASP7147, in the treatment of IBS. Norgine B.V. is having Plenvu, as osmotic laxative in clinical trials and the company entered into an agreement with Noventure to commercialize Gelsectan in Spain, Portugal and Andorra in 2017. Synthetic Biologics, Inc. is developing SYN-010 (modified-release reformulation of lovastatin lactone) as a therapy in irritable bowel syndrome with constipation.
Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/506
Browse 43 Market Data Tables and 34 Figures spread through 194 Pages and in-depth TOC on Irritable Bowel Syndrome Treatment Market by Drug Type (lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron and others), Medical Condition (IBS-constipation and IBS-diarrhea), Distribution Channel (hospital pharmacies, online pharmacies and retail pharmacies) and Region (North America, Latin America, Europe, Asia-Pacific, the Middle East, and, Africa) – Global Forecast to 2025
Key Takeaways of the Irritable Bowel Syndrome Treatment Market:
The global irritable bowel syndrome treatment market is expected to exhibit a CAGR of 9% over the forecast period (2017–2025), owing to the presence of high potential markets, especially in Asia Pacific, Latin America, the Middle East, and Africa
Robust developments in drug therapies and increasing knowledge about physiology of the irritable bowel syndrome is expected to drive the global irritable bowel syndrome treatment market
Some major players operating in the irritable bowel syndrome treatment market include Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., and Ironwood Pharmaceuticals, Inc.
Complete Report Details @ https://www.coherentmarketinsights.com/market-insight/irritable-bowel-syndrome-treatment-market-506
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
1001 4th Ave,
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Irritable Bowel Syndrome Treatment Market to Surpass US$ 2,300 Million Threshold by 2025 here
News-ID: 931597 • Views: 200
More Releases from CMI - Market Research
Adult Vaccines Market, By Types of Vaccines (Monovalent and Multivalent) - Globa …
Vaccination is one of the most effective and safest therapy that protects from diseases and reduces the prevalence of infectious diseases. There are rare side effects associated with vaccinations. Most of the vaccines are recommended on the basis of person’s age, lifestyle, travel destinations, and health conditions such as diabetes, heart diseases, asthma, and chronic obstructive pulmonary disease (COPD). According to Centers for Disease Control and Prevention (CDC), in 2013,
Optogenetics Market, By Sensors (pH Sensors, Genetically Modified Calcium Indica …
Optogenetics is an emerging medical technique, which involves the use of light to control cells in living tissues, especially neurons to help study the characteristics of normal and abnormal brain function. Optogenetics is an emerging field of biotechnology trending among the fields of neuroscience, cardiology, ophthalmology, behavioral science, and other healthcare domains. The technique is widely used to treat neurological disorders such as depression. Depression is caused by chronic stress
X-ray Equipment Market, By Product Type (Computed Tomography, Mobile X-Ray Devic …
X-ray equipment in healthcare is mainly used for imaging of bone structures, tumors, and breast cancer during surgeries, for detecting fractures in bones and teeth, as well as detecting pneumonia. Increasing prevalence of fractures due to osteoporosis, orthopedic disorders, dental problems, and increasing cases of tumor and cancer are expected to boost demand for x-ray equipment in the near future. Rampant advancements in technology and adaptation of advanced medical systems
Sterilization Equipment and Disinfectants Market – Global Industry Insights, T …
Sterilization is process of killing all micro-organisms and pathogens to avoid contamination by means of using physical or chemical treatment. Conversely disinfection is a process to control the growth of micro-organisms and kill a define class of micro-organisms. Disinfection targets narrow spectrum bacteria leaving bacterial spores intact, while sterilization works on broad spectrum micro-organisms. Autoclave uses high pressure and steam to sterilize solid and glass instruments, and liquid mediums in
More Releases for IBS
Global IBS-C Drugs Market Size, Status and Forecast 2022
This report studies the global IBS-C Drugs market, analyzes and researches the IBS-C Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Catalent Pharmaceuticals Solutions Nestle Abbott Laboratories Synergy Pharmaceuticals Sucampo Pharmaceuticals Novartis Pharma Ag Astellas Pharmaceuticals Ardelyx, Inc Synthetic Biologics, Inc Teva Pharmaceutical Industries Bama-Geve, SLU Ferring BV Ironwood Pharmaceuticals, Inc Salix Pharmaceuticals Ltd Norgine B.V Sample of this report is available upon request @ https://www.qyresearchreports.com/sample/sample.php?rep_id=1336446&type=E Table of Contents Global
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA
IBS Scherer presents three product videos on the internet
Action: Who wants to know how industrial parts cleaning is simply working, can get an idea now with just one mouse click on www.ibs-scherer.com. IBS Scherer GmbH, leading manufacturer of environmental-friendly complete solutions for cleaning small parts which are soiled with oil and grease, from Gau-Bickelheim – Germany, informs with three about two-minute product videos, how industrial parts cleaning works with IBS Parts Cleaning Devices. One mouse click and interested visitors
Cathay Pacific selects IBS Solution to help manage staff travel
Cathay Pacific has signed a multi-million dollar contract to implement IBS’ new generation solution, iFly Staff, to automate and improve the management of employee travel. iFly Staff will also be used for Cathay Pacific subsidiaries including sister airline Dragonair. The implementation of iFly Staff will result in an automated staff travel solution that supports the eligibility and entitlements offered to the airline’s employees and their dependants.
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning. This also includes consulting services concerning railway systems issues, such as travel
IBS’ iCargo gives Qantas a leading edge in Freight
~the solution will manage the international freight movements of the carrier ~ Trivandrum, India, 10 June 2010: Qantas, Australia’s national carrier and one of the world’s leading airlines, has implemented IBS’ Cargo Management Solution in its international air freight division, Qantas Freight. Through this deployment, the airline has successfully migrated its global cargo sales, reservations and capacity management functions to IBS’ iCargo platform. iCargo, a new generation end-to-end logistics solution, replaced